New prospects for autoimmune disease therapy: B cells on deathwatch

✍ Scribed by E. William St.Clair; Thomas F. Tedder

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 211 KB
• Volume: 54
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.21525

✦ Synopsis

Dr. St.Clair has served on the advisory boards of Genentech, Cellective Therapeutics (now owned by MedImmune), and Human Genome Sciences. Dr. Tedder has Tedder has received consulting fees (more than $10,000 per year) from Cellective Therapeutics (now owned by MedImmune), has given expert testimony for Idec Pharmaceuticals, and has patents pending with Cellective Therapeutics (now owned by MedImmune).